BR112015011394A2 - uso de pidotimod para tratar a dermatite atópica - Google Patents

uso de pidotimod para tratar a dermatite atópica

Info

Publication number
BR112015011394A2
BR112015011394A2 BR112015011394A BR112015011394A BR112015011394A2 BR 112015011394 A2 BR112015011394 A2 BR 112015011394A2 BR 112015011394 A BR112015011394 A BR 112015011394A BR 112015011394 A BR112015011394 A BR 112015011394A BR 112015011394 A2 BR112015011394 A2 BR 112015011394A2
Authority
BR
Brazil
Prior art keywords
pidotimod
atopic dermatitis
treat atopic
treat
treatment
Prior art date
Application number
BR112015011394A
Other languages
English (en)
Inventor
Mailland Federico
Caserini Maurizio
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of BR112015011394A2 publication Critical patent/BR112015011394A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

1/1 resumo "uso de pidotimod para tratar a dermatite atópica". a presente invenção é direcionada ao uso de pidotimod, ou um sal fisiologicamente aceitável deste, para o tratamento de dermatite atópica. para o tratamento da presente invenção, pidotimod, ou um sal fisiologicamente aceitável deste, é preferivelmente administrado por via tópica.
BR112015011394A 2012-12-19 2012-12-19 uso de pidotimod para tratar a dermatite atópica BR112015011394A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/076086 WO2014094839A1 (en) 2012-12-19 2012-12-19 Use of pidotimod to treat atopic dermatitis

Publications (1)

Publication Number Publication Date
BR112015011394A2 true BR112015011394A2 (pt) 2017-07-11

Family

ID=47520053

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011394A BR112015011394A2 (pt) 2012-12-19 2012-12-19 uso de pidotimod para tratar a dermatite atópica

Country Status (32)

Country Link
US (1) US20150352081A1 (pt)
EP (1) EP2934520B1 (pt)
JP (1) JP6058156B2 (pt)
KR (1) KR20150095772A (pt)
CN (1) CN104797254B (pt)
AU (1) AU2012396941A1 (pt)
BR (1) BR112015011394A2 (pt)
CA (1) CA2889388A1 (pt)
CY (1) CY1118633T1 (pt)
DK (1) DK2934520T3 (pt)
EA (1) EA201591184A1 (pt)
EC (1) ECSP15025570A (pt)
ES (1) ES2615748T3 (pt)
HK (1) HK1210938A1 (pt)
HR (1) HRP20161667T1 (pt)
HU (1) HUE030408T2 (pt)
IL (1) IL239292A0 (pt)
LT (1) LT2934520T (pt)
MA (1) MA38156B1 (pt)
ME (1) ME02559B (pt)
MX (1) MX2015008129A (pt)
PH (1) PH12015501211A1 (pt)
PL (1) PL2934520T3 (pt)
PT (1) PT2934520T (pt)
RS (1) RS55424B1 (pt)
SG (1) SG11201503281QA (pt)
SI (1) SI2934520T1 (pt)
SM (1) SMT201700071B (pt)
TN (1) TN2015000159A1 (pt)
UY (1) UY35197A (pt)
WO (1) WO2014094839A1 (pt)
ZA (1) ZA201502983B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015036009A1 (en) * 2013-09-10 2015-03-19 Polichem S.A. Pidotimod for use in the treatment of inflammation-associated diseases
EP3754806A1 (en) 2019-06-19 2020-12-23 UTC Fire & Security EMEA BVBA Power supply device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231723B (it) * 1989-08-11 1991-12-21 Poli Ind Chimica Spa Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono
WO2003043583A2 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
JP6058156B2 (ja) 2017-01-11
TN2015000159A1 (en) 2016-10-03
PH12015501211A1 (en) 2015-08-17
EP2934520A1 (en) 2015-10-28
EA201591184A1 (ru) 2015-10-30
IL239292A0 (en) 2015-07-30
EP2934520B1 (en) 2016-11-16
HUE030408T2 (en) 2017-05-29
PL2934520T3 (pl) 2017-08-31
MA38156A1 (fr) 2016-08-31
CA2889388A1 (en) 2014-06-26
PT2934520T (pt) 2017-02-16
DK2934520T3 (en) 2017-01-23
AU2012396941A2 (en) 2015-06-18
CN104797254A (zh) 2015-07-22
CN104797254B (zh) 2017-06-06
UY35197A (es) 2014-06-30
SMT201700071B (it) 2017-03-08
HK1210938A1 (en) 2016-05-13
JP2016503042A (ja) 2016-02-01
MX2015008129A (es) 2015-09-23
HRP20161667T1 (hr) 2017-01-27
CY1118633T1 (el) 2017-07-12
ES2615748T3 (es) 2017-06-08
ECSP15025570A (es) 2016-01-29
KR20150095772A (ko) 2015-08-21
WO2014094839A1 (en) 2014-06-26
RS55424B1 (sr) 2017-04-28
ME02559B (me) 2017-02-20
US20150352081A1 (en) 2015-12-10
ZA201502983B (en) 2016-11-30
LT2934520T (lt) 2017-01-10
SI2934520T1 (sl) 2017-03-31
SG11201503281QA (en) 2015-07-30
MA38156B1 (fr) 2017-03-31
AU2012396941A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
BR112016002465A2 (pt) terapia da combinação para o tratamento de câncer
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BR112015012197A8 (pt) usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112012032721A2 (pt) compostos heterocíclicos, sua preparação e sua aplicação terapêutica
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR112013024525A2 (pt) compostos, composição farmacêutica e métodos para tratar condição pré-cancerosa ou câncer em mamífero, pacientes com doença inflamatória crônica ou doença neurodegenerativa e para preparar compostos e usos de compostos e de composição farmacêutica
BR112013026933A2 (pt) uso de uma combinação de pelo menos um carotenoide
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
BR112015011391A2 (pt) uso de pidotimod para tratar a psoríase
BR112015011394A2 (pt) uso de pidotimod para tratar a dermatite atópica
BR112016028402A2 (pt) toxina botulínica para uso no tratamento da paratonia
BR112014022687A8 (pt) uso de uma quantidade eficaz de r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo, composição farmacêutica, r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.